PFE
PFIZER INC
NYSE: PFE · New York, NY · Healthcare
$27.31-0.21 (-0.76%)Closed
Market Cap$155.29B
Cash$1.14Bmost recent
Runwayprofitable
P/E (TTM)20.1EPS $1.36
52-Wk Range$21.87 – $28.75
Avg Volume28.9M3-month
Price & Trading Activity
Daily close with catalyst overlays and trading volume
$27.31+18.5%
Pipeline
Drug candidates sponsored by Pfizer · ClinicalTrials.gov
| Phase | Drug / Candidate | Indications | Status | Next Completion | Trials | |
|---|---|---|---|---|---|---|
| Phase 4 | Palbociclib | Breast Cancer | Completed | 2019-07-25past | 1 | |
| Phase 4 | Bosutinib | Previously Treated PH + CML+5 more | Terminated | 2020-10-13past | 2 | |
| Phase 4 | Rimegepant | Migraine+3 more | Completed | 2024-11-20past | 2 | |
| Phase 4 | Prevenar and Meningitec | Healthy | Completed | — | 1 | |
| Phase 4 | pneumococcus conjugate vaccine | Vaccines, Pneumococcal Conjugate Vaccine | Completed | — | 1 | |
| Phase 3 | ReFacto AF | Hemophilia A | Completed | 2004-08past | 1 | |
| Phase 3 | SPM 907 | Overactive Bladder Syndrome | Completed | 2005-02past | 1 | |
| Phase 3 | Isovorin | Colon Cancer | Completed | 2006-02past | 1 | |
| Phase 3 | fluorouracil | Colorectal Cancer | Completed | 2007-09past | 1 | |
| Phase 3 | Subcutaneous Insulin | Diabetes Mellitus+1 more | Terminated | 2008-09past | 1 | |
| Phase 3 | 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) | Vaccines, Pneumococcal Conjugate Vaccine | Completed | 2009-09past | 1 | |
| Phase 3 | desvenlafaxine succinate (DVS) SR | Vasomotor Symptoms | Completed | 2010-05past | 1 | |
| Phase 3 | Tanezumab | Osteoarthritis+1 more | Terminated | 2010-11-18past | 2 | |
| Phase 3 | 13-valent pneumococcal conjugate vaccine | Vaccines, Pneumococcal+2 more | Completed | 2012-05past | 2 | |
| Phase 3 | Genotropin | Idiopathic Short Stature | Completed | 2012-08past | 1 | |
| Phase 3 | Taliglucerase alfa | Gaucher Disease | Completed | 2014-05past | 1 | |
| Phase 3 | Glasdegib | Acute Myeloid Leukemia+2 more | Completed | 2022-12-02past | 1 | |
| Phase 3 | Apixaban | Deep Vein Thrombosis+2 more | Completed | 2023-09-30past | 2 | |
| Phase 3 | Tucatinib | HER2 Positive Breast Cancer+6 more | Active, not recruiting | 2025-09-05past | 2 | |
| Phase 3 | RESPIRATORY SYNCYTIAL VIRUS PREFUSION F SUBUNIT VACCINE | Respiratory Syncytial Virus (RSV) | Completed | 2025-09-30past | 1 | |
| Phase 3 | PF-06823859 | Myositis | Recruiting | 2027-07-28 | 1 | |
| Phase 3 | Dazukibart | Dermatomyositis+1 more | Recruiting | 2027-11-25 | 1 | |
| Phase 2 | PF-07275315 dose 1 | Moderate to Severe Chronic Obstructive Pulmonary Disease | Recruiting | 2030-10-24 | 1 | |
| Phase 3 | Pregabalin | Diabetic Neuropathy, Painful | Completed | — | 1 | |
| Phase 3 | cefuroxime plus erythromycin | Pneumonia | Completed | — | 1 | |
| Phase 3 | azithromycin SR (Zithromax; compound: CP-62,993) | Bronchitis, Chronic | Completed | — | 1 | |
| Phase 3 | Zyvox® / Linezolid | Bacterial Infections | Completed | — | 1 | |
| Phase 3 | Rapamune® | Kidney Disease | Completed | — | 1 | |
| Phase 3 | Edotecarin | Glioblastoma | Completed | — | 1 | |
| Phase 3 | Linezolid | Bacterial Infections+2 more | Completed | — | 1 | |
| Phase 2 | leflunomide | Brain and Central Nervous System Tumors | Completed | 2006-05past | 1 | |
| Phase 2 | exemestane | Breast Neoplasms | Terminated | 2006-12past | 1 | |
| Phase 2 | AN2690 | Onychomycosis | Completed | 2007-08-31past | 1 | |
| Phase 2 | ARRY-371797, p38 inhibitor; oral | Dental Pain | Completed | 2008-02-11past | 1 | |
| Phase 2 | IMA-638 is a biologic | Asthma | Completed | 2008-05past | 1 | |
| Phase 2 | PF-00885706 | Gastroesophageal Reflux Disease | Terminated | 2008-10past | 1 | |
| Phase 2 | Sunitinib Malate Continuous Daily Dosing | Carcinoma, Renal Cell | Completed | 2010-06past | 1 | |
| Phase 2 | figitumumab | Small Cell Lung Carcinoma | Terminated | 2011-10past | 1 | |
| Phase 2 | PF-04691502 | Early Breast Cancer (Phase 2)+1 more | Terminated | 2012-12past | 1 | |
| Phase 2 | Anti-NGF AB | Neoplasms+1 more | Completed | 2013-02-14past | 1 | |
| Phase 2 | PF-06372865 | Reflex Epilepsy, Photosensitive | Completed | 2017-01-10past | 1 | |
| Phase 2 | VLA15 | Lyme Borreliosis | Completed | 2019-12-18past | 1 | |
| Phase 2 | Tofacitinib | COVID-19 | Withdrawn | 2020-09-16past | 1 | |
| Phase 1 | avelumab | Squamous Cell Carcinoma of the Head and Neck (SCCHN)+1 more | Terminated | 2020-09-29past | 1 | |
| Phase 2 | PF-07976016 | Obesity | Completed | 2025-10-23past | 1 | |
| Phase 2 | Placebo | Asthma+2 more | Completed | 2026-01-21past | 3 | |
| Phase 2 | PG4 | Pneumococcal Disease | Completed | 2026-02-09past | 1 | |
| Phase 1 | MET233 | Obesity and Overweight | Active, not recruiting | 2026-04-15past | 1 | |
| Phase 2 | Etrasimod | Ulcerative Colitis | Recruiting | 2029-06-16 | 1 | |
| Phase 1 | SAM-531 | Alzheimer Disease | Completed | 2008-01past | 1 | |
| Phase 1 | TRU-015 | Lymphoma, B-Cell | Terminated | 2008-04past | 1 | |
| Phase 1 | PF-03716539 | Healthy Volunteers | Completed | 2009-05past | 1 | |
| Phase 1 | Moxidectin | Healthy | Completed | 2009-09past | 1 | |
| Phase 1 | Pegfilgrastim Hospira | Healthy | Completed | 2009-10past | 1 | |
| Phase 1 | [14C]PF00299804 | Carcinoma, Non-Small-Cell Lung | Completed | 2010-02past | 1 | |
| Phase 1 | Inotuzumab Ozogamicin (CMC-544) | Lymphoma, B-Cell | Completed | 2010-03-10past | 1 | |
| Phase 1 | Triazolam | Healthy Volunteers | Withdrawn | 2010-09past | 1 | |
| Phase 1 | PF-00610355 | Pulmonary Disease+2 more | Completed | 2010-09past | 1 | |
| Phase 1 | desvenlafaxine succinate sustained release | Depression - Major Depressive Disorder | Completed | 2010-11past | 1 | |
| Phase 1 | ARRY-334543, EGFR/ErbB2 inhibitor; oral | Advanced Cancer | Completed | 2011-04past | 1 | |
| Phase 1 | tigecycline | Healthy | Completed | 2011-05past | 1 | |
| Phase 1 | ILV-095 300 mg in a 4 to 1 ratio | Plaque Psoriasis | Terminated | 2011-05-20past | 1 | |
| Phase 1 | Tafamidis meglumin | Healthy | Completed | 2011-08past | 1 | |
| Phase 1 | PF-04427429 | Healthy | Completed | 2011-10past | 1 | |
| Phase 1 | dacomitinib | Healthy+1 more | Completed | 2012-08past | 1 | |
| Phase 1 | PF-05082566 | Advanced/Metastatic Solid Tumors | Terminated | 2017-09past | 1 | |
| Phase 1 | PF-04965842 | Healthy Volunteers+1 more | Completed | 2019-11-09past | 2 | |
| Phase 1 | talazoparib | Neoplasms+1 more | Completed | 2021-01-11past | 1 | |
| Phase 1 | PF-06882961 followed by PF-06882961/PF-06865571 | Healthy Volunteer | Completed | 2021-10-10past | 1 | |
| Phase 1 | PF-06882961 20 mg | Diabetes Mellitus, Type 2+2 more | Completed | 2022-02-18past | 1 | |
| Phase 1 | PF-07265028 | Advanced Solid Tumors+5 more | Terminated | 2023-10-16past | 1 | |
| Phase 1 | Zavegepant | Healthy | Completed | 2023-12-12past | 1 | |
| Phase 1 | PF-07976016 Formulation A | Healthy Volunteers | Completed | 2024-12-24past | 1 | |
| Phase 1 | sigvotatug vedotin | Carcinoma, Non-Small Cell Lung+11 more | Recruiting | 2027-06-16 | 1 | |
| Phase 1 | PF-08046050 | Colorectal Neoplasms+5 more | Recruiting | 2029-09-12 | 1 | |
| Phase 1 | Bazedoxifene/conjugated estrogens combination | Healthy | Completed | — | 1 | |
| Phase 1 | SCA-136 | Healthy | Terminated | — | 1 | |
| N/A | sirolimus | Renal Transplantation | Terminated | 2008-02past | 1 | |
| N/A | Unnamed | Ankylosing Spondylitis+3 more | Terminated | 2010-07past | 1 | |
| N/A | Axitinib | Renal Cell Carcinoma | No Longer Available | 2014-03past | 1 | |
| N/A | Etanercept | Arthritis Rheumatoid | Completed | 2018-12-01past | 1 | |
| N/A | CT-P13 | Inflammatory Bowel Diseases+6 more | Completed | 2018-12-31past | 2 | |
| N/A | Unnamed | Rheumatoid Arthritis | Completed | 2019-10-21past | 1 | |
| N/A | Escitalopram | Major Depression | Completed | 2022-11-03past | 1 | |
| N/A | Sunitinib | Carcinoma, Renal Cell+1 more | Completed | 2023-02-23past | 1 | |
| N/A | Inotuzumab Ozogamicin | Adult Relapsed/Refractory B Cell Acute Lymphoblastic Leukemia | Completed | 2023-07-10past | 1 | |
| N/A | Unnamed | Community Acquired Pneumonia (CAP) | Completed | 2023-10-25past | 1 | |
| N/A | nirmatrelvir-ritonavir | COVID-19 (Coronavirus Disease 2019) | Completed | 2024-11-15past | 1 | |
| N/A | ABRYSVO | Respiratory Syncytial Virus Infections | Not yet recruiting | 2026-09-30 | 1 | |
| N/A | Fluconazole | Candidiasis+2 more | Completed | — | 1 |
Valuation
Risk-adjusted NPV
Loading pipeline…
Peer comparison
Cohort check
No peer cohort defined for PFE. Cohorts currently cover gene editing, mRNA, rare-disease gene therapy, and large-cap biotech — more coming soon.